Provisional Translation (as of August 2014) *

PMDA/CPE Notification No. 0822001
August 22, 2014

To: As specified in the Appendix separately

From: Takao Yamori, Ph.D.
Director, Center for Product Evaluation of Pharmaceuticals and Medical Devices Agency

Re: Request for Electronic Clinical Study Data for Pilot Project (The Last Half of FY 2014)

First, we would like to express our gratitude for your understanding and continuous support for the services of the Pharmaceuticals and Medical Devices Agency (PMDA).

PMDA has been making efforts to promote future utilization of electronic clinical study data, with the following details to be included in the third mid-term plan starting in FY 2014: develop a framework for PMDA to enable electronic submission of clinical study data for application of new drugs from FY2016; and improve quality of review and consultation by conducting PMDA-initiated analyses using the clinical study data and by giving indications and advice based on those analyses results. Specifically, PMDA has organized a joint working group with the industry to discuss regulatory and technical issues, and, with the cooperation of your member companies, executed pilot projects in FY2013 and the first half of FY 2014, and contributed to the development of the document "Basic Principles on Electronic Submission of Study Data for New Drug Applications" (Notification number: 0620-6, June 20, 2014, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare).

PMDA will be making efforts to issue technical notices and guides for electronic submission of study data in the near future. Therefore, further examination is required by actually using the electronic study data to determine the necessary electronic data and to examine the methods for utilizing the electronic data in the processes including regulatory review and conformity inspection.

* This English version of the Japanese Notification is provided for reference purposes only. In the event of any inconsistency between the Japanese original and the English translation, the former shall prevail.

In this regard, because a pilot project will be conducted again in the last half of FY 2014, your member companies are kindly requested to cooperate in providing electronic clinical study data for the purpose of examining the future utilization of electronically submitted data and the regulatory review and conformity inspection process.

Although participation in this pilot project is not mandatory, as in FY 2013 and the first half of FY2014, the following electronic data are requested to be provided in principle (see attachment for details). The data that we will be requesting will also be discussed individually in detail with those companies willing to cooperate in this pilot project.

○ Clinical data in conformance to CDISC

1. Data of drug products that are either approved, currently under regulatory review, or scheduled to be reviewed;
2. Data summarized according to the CDISC standards (SDTM and ADaM), and each defined in Define.xml or in a corresponding definition file;
3. Series of datasets from clinical studies that include those of Japanese subjects, along with the analysis program.

As the former pilot projects, the data submitted for this pilot project will be used only for the purpose of testing the future utilization of electronic study data and the regulatory review and conformity inspection process at PMDA, and there will be no influence on the regulatory review and conformity inspection of the products concerned.

We would appreciate that you contact us at the below e-mail address by Friday September 19 if there are any member companies offering to participate in this pilot project regardless of our request. In some cases, specific requests for cooperation will be made individually to your member companies.
Any inquiries about this project may also be directed to the e-mail address below.

We appreciate your understanding regarding this pilot project and your support in requesting your member companies for cooperation. Thank you.

Contact:
E-mail: jisedaiPT @pmda.go.jp

* This English version of the Japanese Notification is provided for reference purposes only. In the event of any inconsistency between the Japanese original and the English translation, the former shall prevail.

Provisional Translation (as of August 2014) *

Advanced Review with Electronic Data Promotion Group
Pharmaceuticals and Medical Devices Agency
(Attachment)

Details of the Electronic Clinical Data to be submitted

○ Clinical data in conformance to CDISC

- Target products
  - New drugs (including follow-on biologics) that are either approved, currently under regulatory review, or scheduled to be reviewed by December 31, 2014.

-Target studies
  - Clinical studies (phases II and III) that include data of Japanese subjects and that indicate the main evidence supporting the efficacy, safety, and dosage and administration in the application data. More than one study per one application (if possible, please submit data from multiple studies included in the application data package).

-Data standard to be used
  - Data should be in conformance with the Clinical Data Interchange Standards Consortium (CDISC) standards
  - As a principle regarding data coding, controlled terminology and code lists recommended by the CDISC are to be used, and the values are to be in SI units.

-Target clinical study data
  - Clinical study data summarized using Study Data Tabulation Model (SDTM) and its definition files such as Define.XML
  - Analysis datasets summarized using Analysis Data Model (ADaM) and its definition files such as Define.XML
  - Analysis program basically intended for ADaM datasets
  - Program for creating ADaM datasets, if created from SDTM datasets
  - Materials described below: (it is desirable to be submitted with datasets, if these have been prepared)
    - ✧ Annotated CRF
    - ✧ Documents providing reviewers with context for datasets (Study Data Reviewer's Guide, Analysis Data Reviewer's Guide and so on.)